FRI0374 BONE MINERAL DENSITY AND TRABECULAR BONE SCORE IN TWO SUBSETS OF SYSTEMIC SCLEROSIS PATIENTS
A. Corrado, A. Mele, A. Trotta, R. Colia, S. Di Bello, F.P. Cantatore. Department of Medical and Surgical Sciences -Rheumatology Clinic, University of Foggia, Foggia, Italy Background: Data concerning the relationship between Systemic Sclerosis (SSc) and alterations of Bone Mineral Density (BMD) are very conflicting. The established standard for measuring BMD is Dual X-ray Absorptiometry (DXA), but it does not provide any informations about the bone microarchitecture, which is a parameter very difficult to evaluate in clinical practice but it is essential to define bone strength. The Trabecular Bone Score (TBS) is a new structural parameter that can be obtained by DXA scanning and it is related to bone microarchitecture and provides data on bone quality irrespective of bone density. Objectives: The aim of this study is to evaluate the differences in BMD and TBS values in two subsets of patients with SSc (limited and diffuse cutaneous disease -lSSc and dSSc) and to analyse their possible relationship with the parameters of body mass composition and phospho-calcium metabolism. Methods: 64 post-menopausal patients classified according to Leroy as limited cutaneous (lSSc) or diffuse cutaneous (dSSc) SSc, were recruited. The following clinical parameters were evaluated: internal organ involvement, degree of skin involvement (Rodnan Skin Score), bone mass index (BMI). For each recruited patient, spine and hip BMD, TBS and body mass composition (lean and fat mass, total bone mineral content -BMC) were assessed by DXA. Serum calcium, phosphorus, alkaline phosphatase, intact parathyroid hormone (PTH) and 25-hydroxyvitamin D (25 OHD) were also measured. Results: BMD at femoral neck and spine was significantly higher in lSSc compared to dSSc patients (p<0,04). In lSSc subjects also BMC was significantly higher compared to dSSc ones (p<0,01) but, interestingly the TBS was significantly lower (p<0,03). lSSc patients presented a higher values of fat mass compared to dSSc (p<0,05), with a slightly higher BMI (which did not reach statistical significance). 25OH serum levels were higher in lSSc group, whereas no differences between lSSc and dSSc in serum calcium, phosphorus, alkaline phosphatase were observed.
Conclusions:
The presented preliminary data show that in SSc patients with limited cutaneous disease, the BMD values are higher compared to patient with diffuse cutaneous disease; nevertheless in this subset (lSSc) bone quality seem to be reduced, as TBS values are significantly lower. Higher BMC values and serum 25OHD levels observed in lSSc patients could be among the factors that contribute to increasing BMD in this clinical subset. Further analysis should be performed to identify the possible causes of the reduced bone quality in spite of higher BMD in lSSc patients, such as the study of serum adipokines, considering that the presented data show a great fat mass in patients with limited cutaneous disease. [ARB] , and 4th alpha-blocker). In mild pulmonary arterial hypertension (PAH), only 45% of the experts agreed with the old algorithm. The majority suggested first phosphodiesterase 5 inhibitors (PDE5i) or endotelin receptor antagonists (ERA) plus PDE5i, then prostanoids. In severe PAH, 65% agreed with the preexistent scheme (1st prostanoids, 2nd ERA plus PDE5i, 3rd ERA plus prostanoids). For mild Raynaud's phenomenon (RP) 66% agreed with the previous algorithm (1st CCB, 2nd adding PDE5i, 3rd ARB or switching to another CCB, 4th prostanoids). Regarding severe RP, 52% agreed with previous (1st CCB, 2nd adding PDE5i, 3rd ERA, 4th prostanoids). Conversely, 60% of the experts did not agree with the prior active digital ulcer (DU) treatment, suggesting 1st CCB, 2nd PDE5i, 3rd prostanoids. For interstitial lung disease (ILD), for induction only 24% agreed with the older proposal. Experts suggested 1st mofetil mycophenolate (MMF), 2nd intravenous (IV) cyclophosphamide (CYP), 3rd Rituximab. There was a 65% agreement on ILD maintenance (1st MMF, 2nd azathioprine [AZA], 3rd IV CYP, 4th oral CYP). For skin involvement, agreement for patients with a modified Rodnan skin score (mRSS) of 10 was 57% (1st methotrexate [MTX] ), 2nd MMF); if the mRSS was 24, 32% suggested 1st MMF, 2nd MTX; and mRSS 32, 36% chose 1st MTX, 2nd MMF, 3rd IV CYP, 4th autologous stem cell transplantation (ASCT). In inflammatory arthritis 45% agreed with the previous algorithm, whereas others suggested 1st MTX, 2nd low dose steroids, 3rd hydroxychloroquine, 4th rituximab or tocilizumab. Conclusions: There remains some disagreement for 2nd line treatment of SSc. Combination of PDE5i and ERA are prescribed now in mild PAH treatment. Prostanoids have been incorporated as 3rd line agents in active DU treatment. MMF is the new 1st line treatment for ILD induction and rituximab the 3rd. IV CYA and ASCT were recommended as 3rd and 4th line treatments in patients with severe skin involvement. Rituximab and tocilizumab have been incorporated into inflammatory arthritis treatment. This can guide therapy in SSc. 
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